Bailard, Inc. Crispr Therapeutics Ag Transaction History

Bailard, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 03, 2021	SELL	$79.67 - $173.23 $1.2 Million - $2.6 Million	-15,000 Closed	0 $0
Q2 2020 Aug 12, 2020	SELL	$38.5 - $76.05 $1.46 Million - $2.89 Million	-38,000 Reduced 71.7%	15,000 $1.1 Million
Q1 2020 Apr 16, 2020	BUY	$33.68 - $62.53 $1.79 Million - $3.31 Million	53,000 New	53,000 $2.25 Million

491

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.74B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.